Amedica Corporation (AMDA) Upgraded at ValuEngine

ValuEngine upgraded shares of Amedica Corporation (NASDAQ:AMDA) from a sell rating to a hold rating in a report released on Friday.

Separately, Maxim Group lowered shares of Amedica Corporation from a buy rating to a hold rating in a research report on Monday, September 25th.

Shares of Amedica Corporation (NASDAQ:AMDA) opened at $3.37 on Friday. Amedica Corporation has a 1 year low of $3.12 and a 1 year high of $13.08.

TRADEMARK VIOLATION WARNING: This report was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2017/11/14/amedica-corporation-amda-upgraded-at-valuengine.html.

An institutional investor recently raised its position in Amedica Corporation stock. Vanguard Group Inc. lifted its holdings in Amedica Corporation (NASDAQ:AMDA) by 7.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 595,866 shares of the medical equipment provider’s stock after acquiring an additional 39,603 shares during the period. Vanguard Group Inc. owned approximately 2.26% of Amedica Corporation worth $226,000 as of its most recent filing with the SEC. 4.95% of the stock is owned by hedge funds and other institutional investors.

Amedica Corporation Company Profile

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amedica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply